** Brokerage UBS upgrades healthcare conglomerate CVS Health CVS.N to "buy" from "neutral," raising PT to $79 from $67
** New PT represents a ~13.2% upside to the stock's last close
** Shares of CVS up 2.2% at $70.1 premarket
** UBS says CVS has managed its Medicare Advantage plans well, giving the brokerage more confidence in its future performance
** UBS believes CVS will reduce its debt by late 2026, allowing for more share buybacks and further earnings growth
** UBS says it does not expect any major negative changes from drug pricing rules or its Star ratings in the near term
** As of last close, CVS stock up 52.8% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。